Alvotech(US:ALVO) ZACKS·2025-11-12 23:56Core Insights - Alvotech reported a quarterly loss of $0.02 per share, which was better than the Zacks Consensus Estimate of a loss of $0.05, but a decline from earnings of $0.19 per share a year ago, resulting in an earnings surprise of -140.00% [1] - The company generated revenues of $113.86 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 11.6%, but showing an increase from $102.99 million in the same quarter last year [2] - Alvotech shares have decreased by approximately 57.8% year-to-date, contrasting with a 16.4% gain in the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.03, with expected revenues of $159.54 million, and for the current fiscal year, the estimate is $0.07 on revenues of $576.57 million [7] - The trend of estimate revisions for Alvotech was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Alvotech belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Zealand Pharma A/S, is expected to report a quarterly loss of $1.23 per share, reflecting a year-over-year change of -119.6%, with revenues anticipated to be $4.66 million, a significant increase of 616.2% from the previous year [9][10]